A Phase II Trial of Brivanib in Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Brivanib, an oral, multi-targeted tyrosine kinase inhibitor with activity against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR) was investigated as a single agent in a phase II trial to assess the activity and tolerability in recurrent or persistent...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecol Oncol
Hauptverfasser: Powell, Matthew A., Sill, Michael W., Goodfellow, Paul J., Benbrook, Doris M., Lankes, Heather A., Leslie, Kimberly K., Jeske, Yvette, Mannel, Robert S., Spillman, Monique A, Lee, Paula S., Hoffman, James S., McMeekin, D. Scott, Pollock, Pamela M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4278402/
https://ncbi.nlm.nih.gov/pubmed/25019571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.07.083
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge